Incyte Corp. (INCY): Price and Financial Metrics
INCY Price/Volume Stats
| Current price | $66.61 | 52-week high | $70.36 |
| Prev. close | $65.17 | 52-week low | $50.27 |
| Day low | $65.27 | Volume | 937,069 |
| Day high | $66.95 | Avg. volume | 2,424,581 |
| 50-day MA | $64.25 | Dividend yield | N/A |
| 200-day MA | $60.00 | Market Cap | 14.96B |
INCY Stock Price Chart Interactive Chart >
Incyte Corp. (INCY) Company Bio
ncyte is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. (Source:Wikipedia)
Latest INCY News From Around the Web
Below are the latest news stories about INCYTE CORP that investors may wish to consider to help them evaluate INCY as an investment opportunity.
12 Most Promising Gene Editing Stocks According to Hedge FundsIn this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can take a look at the 5 Most Promising […] |
13 Most Promising Healthcare Stocks According to AnalystsIn this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […] |
AI Meets Biotech: 3 Top Stocks Transforming Medical ScienceThe AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. |
The 3 Most Undervalued Biotech Stocks to Buy in DecemberBiotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. |
Incyte Stock Is the S&P 500’s Top Performer. Here’s Why It’s Surging.Shares of biopharmaceutical company Incyte were on track Tuesday for their best trading session in more than six years. The stock rose 8.6% to $61.97 on Tuesday, putting Incyte shares on pace for their largest increase since Aug. 30, 2017, when they gained 11%, according to Dow Jones Market Data. It was the top performer in the on Tuesday. |
INCY Price Returns
| 1-mo | 3.46% |
| 3-mo | 5.36% |
| 6-mo | 16.90% |
| 1-year | 10.34% |
| 3-year | -12.25% |
| 5-year | -17.98% |
| YTD | 6.08% |
| 2023 | -21.83% |
| 2022 | 9.43% |
| 2021 | -15.61% |
| 2020 | -0.39% |
| 2019 | 37.32% |
Continue Researching INCY
Want to do more research on Incyte Corp's stock and its price? Try the links below:Incyte Corp (INCY) Stock Price | Nasdaq
Incyte Corp (INCY) Stock Quote, History and News - Yahoo Finance
Incyte Corp (INCY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...